DELAWARE, Ohio, April 25, 2025 (GLOBE NEWSWIRE) -- Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, announced today it has been recognized with a Gold and Silver Stevie® Award in the Management - Manufacturing category of the Annual American Business Awards®. Ole Rosgaard, President and CEO of Greif, was awarded with a Gold Stevie Award for Achievement in Management – Manufacturing, and Greif was awarded with a Silver Stevie Award for Company of the Year - Large ...

ZEELAND, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today reported financial results for the three months ended March 31, 2025. 1st Quarter 2025 Summary Net sales of $576.8 million, a 2% decrease compared to the first quarter of 2024, versus light vehicle production that was down 3% quarter over quarter in the Company's primary market ...

GREENWICH, Conn., April 25, 2025 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended March 31, 2025. On April 22, 2025, our Board of Directors declared the following distributions on our common stock: Month EndingRecord DatePayment DateAmount Per ShareJuly 31, 2025July 17, 2025<td style="border-t ...

The Peak by LGI Homes at Second Creek Farm The Peak by LGI Homes at Second Creek Farm features four bedrooms, two-and-a-half bathrooms, and a covered porch. COMMERCE CITY, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) announced the opening of a new section at Second Creek Farm, a premier community located in Commerce City, Colorado. This expanded section of 240 lots offers homebuyers an incredible opportunity to secure an upgraded, affordable new home in a vibrant and highly d ...

NEW YORK, NY, April 25, 2025 (GLOBE NEWSWIRE) -- Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ: GFAI, GFAIW), a global integrated security provider specializing in secured logistics, Artificial Intelligence (AI), and Robot-as-a-Service (RaaS), today announced it will host a conference call at 8:30 a.m. Eastern Time on Monday, April 28, 2025, to discuss the Company’s financial results for the year ended December 31, 2024. The call will also include an update on the Company's corporate ...

ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsper ...

文章核心观点 - 临床阶段专业制药公司SciSparc与Clearmind合作，就针对厌食症、贪食症和其他饮食失调症的专有疗法提交新国际专利申请 [1] 行业情况 - 饮食失调症是严重心理健康问题，影响个人健康、情绪和日常功能，是年轻女性十大致残原因之一，死亡率高于其他精神疾病 [3] - 全球约7亿人受饮食失调症影响，儿童和青少年患者显著增加，2000 - 2018年全球患病率从3.4%升至7.8% [3] 公司合作成果 - SciSparc与Clearmind合作提交针对厌食症、贪食症和其他饮食失调症的新国际专利申请 [1] - 专利申请涵盖3 - 甲基甲卡西酮（3 - MMC）与SciSparc的棕榈酰乙醇酰胺（PEA）联用，旨在解决饮食失调症相关复杂神经生物学和心理因素，提供新治疗途径 [2] 公司情况 SciSparc Ltd. - 临床阶段专业制药公司，由资深高管和科学家团队领导，专注基于大麻素制药技术和资产组合开发 [4] - 目前开展基于四氢大麻酚（THC）和/或非精神活性大麻二酚（CBD）的药物开发项目，如治疗图雷特综合症、阿尔茨海默病及激越的SCI - 110，治疗自闭症谱系障碍（ASD）和癫痫持续状态的SCI - 210 [4] - 拥有一家专注于在亚马逊市场销售大麻籽油产品子公司的控股权 [4] Clearmind Medicine Inc. - 临床阶段迷幻药制药生物技术公司，专注发现和开发新型迷幻药衍生疗法，解决包括酒精使用障碍在内的普遍且未得到充分治疗的健康问题 [5] - 主要目标是研究开发基于迷幻药的化合物，并将其作为受监管药物、食品或补充剂商业化 [5] - 知识产权组合包括19个专利家族和31项已授权专利，有意在必要时为其化合物寻求更多专利，并会把握机会获取更多知识产权以丰富组合 [6] - 普通股在纳斯达克以“CMND”为代码、在法兰克福证券交易所以“CWY0”为代码上市交易 [6]

Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone ...

April 25, 2025Announcement no. 13 Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them. 1 Details of the person discharging managerial responsibilities/person ...

April 25, 2025Announcement no. 12 BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes Completion of share capital increase COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), decided on April 15, 2025, to complete a private placement of 25,000,000 new shares to existing larg ...